vertex pharmaceuticals inc
(VRTX:NASDAQ GS)

Executive Profile*

Background*

Dr. Peter Mueller has been the Chief Scientific Officer and Executive Vice President of Global Research & Development at Vertex Pharmaceuticals Inc. since July 21, 2003 and May 2009 respectively. In this role, Dr. Mueller is responsible for Vertex's research and drug discovery activities and directs research strategy across the Vertex Pharmaceuticals Inc.'s Cambridge, San Diego, and Oxford, UK, sites. He served as Executive Vice President of Drug Discovery and Innovation ... at Vertex from February 2006 to May 2009 and its Senior Vice President of Drug Discovery and Innovation from July 21, 2003 to February 2006. Dr. Mueller, who joined Vertex from Boehringer Ingelheim Pharmaceuticals, He served as Chief Operating Officer and Director of Research at Amarillo Biosciences Inc. since April 15, 2008. He was actively involved in the development of strategic alliances and business opportunities with other companies and organizations. Dr. Mueller has more than 20 years of global experience in the Pharmaceutical industry. Most recently, from April 2001 until joining Amarillo, Dr. Mueller served as President of Epicenter Consulting, Inc. Previously he served as Vice President of Global Marketing & Medical Information and Technology for Aventis Pharmaceuticals. Prior to that position, he served as Vice President of Global Business & Marketing Services for Hoechst Marion Roussel. He served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for the development of all drug candidates of its worldwide portfolio in North America. He led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery of 12 development candidates, including: seven Phase I compounds, five Phase IIa candidates, three Phase IIb/III drug candidates and six new drug applications. Dr. Mueller began his career at Boehringer Ingelheim in 1984 where he held several positions in basic research, medicinal chemistry and management prior to his appointment as Senior Vice President, Research and Development in 1997. He serves as a Member of the Scientific Advisory Board at Vertex Pharmaceuticals Incorporated. Dr. Mueller is a member of various scientific organizations, including Gesellschaft Deutscher Chemiker, Royal Society of Chemistry, The RNA Society and the American Association for the Advancement of Science. Dr. Mueller is named as an inventor on 43 filed and granted patents. Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he is also a faculty member holding a professorship in theoretical organic chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University. Dr. Mueller is a pharmacist with a Ph.D. degree in pharmaceuticals from the University of Mainz, Germany.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
VRTX:US	$80.95 USD	+1.48

COMPETITOR COMPENSATION